HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.

AbstractAIMS:
Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies.
METHODS AND RESULTS:
Ceramides and PCs were analysed using liquid chromatography-mass spectrometry (LC-MS) in three studies: WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95% confidence interval) per standard deviation were 1.44 (1.28-1.63) in WECAC, 1.47 (1.34-1.61) in the LIPID trial, and 1.69 (1.31-2.17) in KAROLA]. In addition, a combination of the risk score with high-sensitivity troponin T increased the HRs to 1.63 (1.44-1.85) and 2.04 (1.57-2.64) in WECAC and KAROLA cohorts, respectively. The C-statistics in WECAC for the risk score combined with sex and age was 0.76 for CVD death. The ceramide-phospholipid risk score showed comparable and synergistic predictive performance with previously published CVD risk models for secondary prevention.
CONCLUSION:
A simple ceramide- and phospholipid-based risk score can efficiently predict residual CVD event risk in patients with coronary artery disease.
AuthorsMika Hilvo, Peter J Meikle, Eva Ringdal Pedersen, Grethe S Tell, Indu Dhar, Hermann Brenner, Ben Schöttker, Mitja Lääperi, Dimple Kauhanen, Kaisa M Koistinen, Antti Jylhä, Kevin Huynh, Natalie A Mellett, Andrew M Tonkin, David R Sullivan, John Simes, Paul Nestel, Wolfgang Koenig, Dietrich Rothenbacher, Ottar Nygård, Reijo Laaksonen
JournalEuropean heart journal (Eur Heart J) Vol. 41 Issue 3 Pg. 371-380 (01 14 2020) ISSN: 1522-9645 [Electronic] England
PMID31209498 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Validation Study)
Copyright© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
Chemical References
  • Biomarkers
  • Ceramides
  • Phospholipids
Topics
  • Aged
  • Atherosclerosis (blood, diagnosis)
  • Biomarkers (blood)
  • Ceramides (blood)
  • Chromatography, Liquid (methods)
  • Coronary Angiography
  • Coronary Artery Disease (blood, diagnosis)
  • Female
  • Humans
  • Male
  • Mass Spectrometry (methods)
  • Middle Aged
  • Phospholipids (blood)
  • Prognosis
  • Risk Assessment (methods)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: